Abstract
The discovery and utilization of RNA-guided surveillance complexes, such as CRISPR-Cas9, for sequencespecific DNA or RNA cleavage, has revolutionised the process of gene modification or knockdown. To optimise the use of this technology, an exploratory race has ensued to discover or develop new RNA-guided endonucleases with the most flexible sequence targeting requirements, coupled with high cleavage efficacy and specificity. Here we review the constraints of existing gene editing and assess the merits of exploiting the diversity of CRISPR-Cas effectors as a methodology for surmounting these limitations.
Original language | English |
---|---|
Pages (from-to) | 91-106 |
Number of pages | 16 |
Journal | Journal of Biomedical Research |
Volume | 35 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2021 |